Cambridge Investment Research Advisors
MBRX icon

Cambridge Investment Research Advisors’s Moleculin Biotech MBRX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-511
Closed -$7K – 3906
2025
Q3 		$7K Hold
511
– – ﹤0.01% 3707
2025
Q2 		$4K Hold
511
– – ﹤0.01% 3604
2025
Q1 		$12K Buy
+511
New +$17.2K ﹤0.01% 3478

Other funds holding MBRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
PWPS
Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Cambridge Investment Research Advisors's MBRX Position: Q4 2025 in Review

Cambridge Investment Research Advisors sold out of Moleculin Biotech (MBRX) in Q4 2025, closing a stake of 511 shares — an estimated $7K sold.

Cambridge Investment Research Advisors first reported a position in MBRX in Q1 2025 and held it in 3 quarters. The position peaked at $12K in Q1 2025. 17 funds tracked by Wall St. Rank hold MBRX as of Q4 2025.

  • Cambridge Investment Research Advisors reported no remaining Moleculin Biotech position as of Q4 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 511 Moleculin Biotech shares in Q4 2025, an estimated $7K.
  • Cambridge Investment Research Advisors first reported a position in Moleculin Biotech in Q1 2025 and held it in 3 quarters.
  • Cambridge Investment Research Advisors's Moleculin Biotech position peaked at $12K in Q1 2025.
  • 17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2025, filed 5 Feb 2026.